Professor of Medicine
University of California, San Francisco
San Francisco, CA
Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine at the University of California San Francisco School of Medicine. Dr. Palefsky completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University in 1989. He then joined the faculty at the University of California, San Francisco, where he remains to this day. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Helen Diller Family Comprehensive Cancer Center. He has pioneered diagnostic and treatment methods for anal intraepithelial neoplasia (AIN) and has been an advocate for screening and treatment of AIN in high-risk populations to prevent anal cancer. He is the chair of the Anal Cancer/HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study designed to determine whether treatment of anal cancer precursor lesions prevents the development of anal cancer. He is the vice-chair elect of the National Cancer Institute-supported AIDS Malignancy Consortium. He is the founder and past president of the International Anal Neoplasia Society and is the past president of the International Papillomavirus Society (IPVS). He is a member of the American Society for Clinical Investigation and Association of American Physicians.
Disclosure: Janssen: Invited speaker at a conference- I am not on their speakers' bureau.
Merck and Co.: Advisory Board, Other Financial or Material Support, Research Grant, Travel support
Ubiome: Advisory Board, Grant/Research Support, Shareholder
Vaccitech: Consultant, Other Financial or Material Support, Supplies in kind for a research study
Vir Biotechnology: Consultant, Shareholder
Virion Technologies: Consultant, Shareholder
Saturday, October 5
2:04 PM – 2:23 PM